Dermatology Research
MC1R Receptor Agonist
Clinical & Preclinical
Pigmentation & Photoprotection
Melanotan I (Afamelanotide) is a synthetic α-melanocyte-stimulating hormone (α-MSH) analog designed to selectively activate the melanocortin-1 receptor (MC1R). Activation of this receptor stimulates eumelanin production within melanocytes, enhancing the skin’s natural pigmentation and photoprotective mechanisms. Because of its high selectivity for MC1R, Melanotan I has become one of the most extensively studied melanocortin peptides in dermatological and photobiology research.
Unlike broader melanocortin receptor agonists, Melanotan I primarily targets pathways involved in melanin synthesis, ultraviolet (UV) defense, and skin photoprotection while producing minimal activity at other melanocortin receptor subtypes. Clinical and preclinical investigations have demonstrated its ability to increase eumelanin production, reduce UV-induced cellular damage, and support the skin’s natural defense mechanisms, generating significant scientific interest in pigmentation disorders and photosensitivity research.
Current research continues to investigate Melanotan I across a broad range of applications including photoprotection, pigmentation biology, oxidative stress, DNA repair following UV exposure, and melanocyte physiology. As with all compounds featured in the ChoicePeps Research Library, Melanotan I is presented exclusively for educational and scientific reference purposes and is intended for research use only.
Clinical and preclinical research investigating Melanotan I (Afamelanotide) and its ability to stimulate eumelanin production, enhance pigmentation, and improve the skin's natural defense against ultraviolet (UV) radiation.
Clinical studies evaluating Melanotan I in patients with photosensitivity disorders, demonstrating improved photoprotection, increased melanin production, and reduced susceptibility to UV-induced skin damage.
Comprehensive research examining melanocortin-1 receptor (MC1R) signaling, melanocyte biology, eumelanin synthesis, pigmentation regulation, and the therapeutic potential of melanocortin analogs including Melanotan I.
Current peer-reviewed investigations exploring Melanotan I's role in photoprotection, oxidative stress reduction, DNA repair following UV exposure, pigmentation disorders, and long-term skin health research.
Current preclinical and clinical research is investigating Melanotan I across multiple areas of pigmentation biology, melanocortin signaling, photoprotection, ultraviolet (UV) defense, and dermatological science.
Melanotan I (Afamelanotide) is a synthetic α-melanocyte-stimulating hormone (α-MSH) analog that selectively activates the melanocortin-1 receptor (MC1R). It has been extensively studied for its ability to stimulate eumelanin production, enhance the skin’s natural pigmentation, and improve protection against ultraviolet (UV) radiation. It remains an important research compound in dermatology and photobiology.
Melanotan I binds to and activates MC1 receptors located on melanocytes. Activation of these receptors increases eumelanin synthesis, leading to darker skin pigmentation while enhancing the skin’s natural defense against UV-induced cellular damage. Researchers continue to investigate its role in photoprotection, pigmentation biology, and skin health.
Researchers are interested in Melanotan I because of its highly selective action on the melanocortin system and its demonstrated ability to increase eumelanin production. Clinical and preclinical studies have explored its potential for improving photoprotection, reducing UV-induced DNA damage, and supporting individuals with photosensitivity disorders.
Numerous peer-reviewed studies have investigated Melanotan I in the fields of dermatology, melanocyte biology, and photomedicine. Published research has examined pigmentation, MC1 receptor signaling, ultraviolet protection, oxidative stress reduction, and the therapeutic potential of melanocortin receptor agonists.
Melanotan I primarily influences the melanocortin-1 receptor (MC1R) pathway, stimulating melanogenesis and eumelanin production. Research also suggests effects on cellular photoprotection, oxidative stress responses, DNA repair following UV exposure, and overall skin defense mechanisms.
The research peptide Melanotan I itself is not FDA approved as a research compound. However, Afamelanotide, a pharmaceutical form of Melanotan I, has received regulatory approval in certain countries—including FDA approval in the United States for a specific rare photosensitivity disorder. Within the ChoicePeps Research Library, Melanotan I is presented exclusively for laboratory and scientific research purposes.
Current research is investigating Melanotan I across multiple areas including photoprotection, pigmentation disorders, melanocyte function, ultraviolet-induced skin damage, oxidative stress, DNA repair mechanisms, and long-term dermatological health. Ongoing studies continue to explore its role in skin physiology and melanocortin receptor biology.
The information presented in the ChoicePeps Research Library is provided solely for educational and informational purposes. Content is compiled from publicly available scientific literature and is intended to summarize current areas of research involving investigational compounds.
The material presented on this page has not been evaluated by the U.S. Food and Drug Administration (FDA) and should not be interpreted as medical advice, treatment recommendations, or evidence of clinical efficacy. Scientific understanding continues to evolve as additional laboratory and clinical research becomes available.
ChoicePeps does not make claims regarding the diagnosis, treatment, cure, or prevention of any disease. Visitors are encouraged to consult original peer-reviewed publications when reviewing scientific findings.
